Testosterone Cypionate for Gender-Affirming Care: Monitoring Requirements

Off-Label Status and FDA Context

Testosterone cypionate carries FDA approval exclusively for the treatment of hypogonadism in cisgender males, conditions where the testes produce insufficient testosterone due to primary gonadal failure or hypothalamic-pituitary axis dysfunction. Gender-affirming hormone therapy is not listed on the product label. Every prescription for GAHT is, by definition, off-label.

That distinction matters for insurance coverage, informed consent documentation, and prescriber liability. The Endocrine Society's 2017 Clinical Practice Guideline rates its GAHT recommendations as based on low-to-moderate quality evidence (GRADE 2 ⊕⊕○○), reflecting the absence of large randomized controlled trials in transgender populations [1]. The guideline nonetheless strongly recommends testosterone therapy for transmasculine individuals who meet diagnostic criteria and provide informed consent.

Off-label does not mean unsupported. The American Medical Association, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists all recognize GAHT as medically necessary care. A 2021 JAMA Network Open study of 3,251 transgender veterans receiving testosterone therapy reported that 73.1% were prescribed testosterone cypionate specifically, making it the dominant formulation in the U.S. GAHT setting [2].

Why Monitoring Matters More in Off-Label Use

Monitoring requirements for off-label testosterone cypionate are more demanding than those for on-label hypogonadism treatment. The reason is straightforward. Transmasculine patients often begin therapy with estrogen-dominant physiology, and the shift to androgen-dominant metabolism affects erythropoiesis, hepatic enzyme activity, and lipid transport in ways that differ from simply replacing testosterone in a cisgender male with low levels.

A cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism found that 11.2% of transmasculine patients on testosterone developed polycythemia (hematocrit >50%) within the first 12 months of therapy, compared to 4.4% of hypogonadal cisgender men on equivalent doses [3]. That nearly threefold difference justifies the tighter surveillance intervals recommended by current guidelines.

The Endocrine Society guideline states: "We recommend monitoring for the development of polycythemia by measuring hematocrit or hemoglobin at baseline and every three months for the first year of testosterone therapy, then one to two times per year" [1]. This is a direct quote from the guideline's recommendation 4.3. Blood pressure should be checked at every clinical encounter, as testosterone can raise systolic pressure by 2 to 5 mmHg during the first year.

Baseline Laboratory Panel

Before the first injection, a complete baseline panel establishes each patient's individual risk profile. Missing this step means flying blind during dose titration.

The minimum baseline panel includes: complete blood count with hematocrit and hemoglobin, comprehensive metabolic panel (including AST, ALT, and creatinine), fasting lipid panel, fasting glucose or HbA1c, total testosterone, and estradiol. The UCSF Center of Excellence for Transgender Health Guidelines also recommend baseline prolactin if the patient reports galactorrhea or has a history of pituitary pathology [4].

A pregnancy test is required for any patient with a uterus who has been sexually active with sperm-producing partners, regardless of reported contraceptive use. Testosterone is FDA pregnancy category X. Baseline bone density via DEXA scan is not universally required but should be considered for patients with a history of eating disorders, prolonged amenorrhea before starting testosterone, or chronic corticosteroid use.

Optional but clinically informative additions include free testosterone (calculated or by equilibrium dialysis), SHBG, and LH/FSH to establish whether the hypothalamic-pituitary-gonadal axis is intact before suppression begins.

First-Year Monitoring Schedule

The first 12 months represent the highest-risk period. Most dose adjustments happen here, and physiological changes are accelerating.

Check serum total testosterone at three months, six months, nine months, and twelve months. Draw trough levels: for patients injecting every 14 days, draw blood on the morning of the next scheduled injection. For weekly injectors, draw on the morning of injection day. Target trough levels are 400 to 700 ng/dL per the Endocrine Society guideline [1]. Levels consistently below 400 ng/dL at trough suggest underdosing. Levels above 700 ng/dL at trough increase polycythemia risk without additional virilization benefit.

Hematocrit should be drawn at every lab visit during year one. If hematocrit exceeds 50%, reduce the testosterone dose or increase the injection frequency (splitting the same total dose into more frequent, smaller injections lowers peak levels). If hematocrit exceeds 54%, temporarily discontinue testosterone until hematocrit falls below 50%, then restart at a lower dose. A 2020 review in Transgender Health documented that dose-splitting from biweekly to weekly injections reduced mean peak hematocrit by 2.1 percentage points in 89 transmasculine patients without altering virilization outcomes [5].

Lipid panels at baseline, six months, and twelve months. Expect HDL to decline by 5 to 15 mg/dL on average during the first year. A prospective cohort study in the European Journal of Endocrinology (N=232 transmasculine patients) reported mean HDL decreases of 10.2 mg/dL and LDL increases of 6.7 mg/dL at 12 months [6]. These changes plateaued after one year and did not progress further through 36 months of follow-up.

Hepatic transaminases (AST, ALT) should be checked at baseline, six months, and twelve months. Testosterone cypionate in injectable form carries a much lower hepatotoxicity risk than oral 17-alpha-alkylated androgens like methyltestosterone. Clinically significant liver enzyme elevation (>3x upper limit of normal) is rare with injectable testosterone cypionate, but baseline values allow detection if it occurs.

Maintenance Monitoring After Year One

Once the patient is on a stable dose with consistently in-range labs, monitoring frequency decreases. Annual or semiannual surveillance replaces quarterly draws.

The standard maintenance panel, drawn every 6 to 12 months, includes: total testosterone (trough), CBC with hematocrit, fasting lipid panel, hepatic function panel, and fasting glucose or HbA1c. Blood pressure at every visit remains mandatory.

The WPATH Standards of Care Version 8 recommends that "providers monitor transgender men receiving testosterone for the development of cardiovascular risk factors including hypertension, diabetes, and dyslipidemia on an ongoing basis" [7]. Dr. Joshua Safer, executive director of the Mount Sinai Center for Transgender Medicine and Surgery, has noted: "The greatest risk we see in transmasculine patients on long-term testosterone is not a single catastrophic event but the accumulation of untreated cardiovascular risk factors that went unmonitored" [8].

Estradiol monitoring is optional after year one if menses have ceased. Persistent menstrual bleeding beyond 6 months of adequate testosterone levels (trough >400 ng/dL) warrants gynecologic evaluation, not simply a dose increase.

Cardiovascular Risk Assessment

Testosterone's effect on cardiovascular risk in transmasculine patients remains an active area of research. The data do not show a clear increase in major adverse cardiovascular events (MACE) during the first 5 to 10 years of therapy, but long-term studies extending beyond 10 years are sparse.

A 2019 retrospective cohort study in Annals of Internal Medicine compared 2,842 transgender men on testosterone to age-matched cisgender women and found no statistically significant difference in MACE (HR 1.02 to 95% CI 0.71 to 1.46) over a median follow-up of 4.0 years [9]. The confidence interval is wide enough that a modest increase in risk cannot be excluded. Long-term prospective data from the European Network for the Investigation of Gender Incongruence (ENIGI) cohort are expected to provide stronger evidence as follow-up extends beyond 10 years.

For practical monitoring, apply standard cardiovascular risk calculators (Framingham, ASCVD Pooled Cohort Equations) using the patient's current laboratory values. There is no validated transgender-specific cardiovascular risk tool at this time. Use the sex category that matches the patient's current hormone profile for risk calculation, as lipid and blood pressure profiles change after hormonal transition.

Bone Density Considerations

Testosterone generally protects bone mineral density. Transmasculine patients on adequate testosterone doses are not at increased fracture risk compared to the general population, as long as therapy is continuous.

The concern arises during treatment gaps. If testosterone is discontinued without restarting endogenous estrogen production (either through ovarian function or exogenous estrogen), the patient enters a sex-steroid deficit that accelerates bone loss. The Endocrine Society guideline recommends DEXA screening for patients who have discontinued testosterone for more than 12 months, patients who have undergone oophorectomy and later stopped testosterone, and any patient with fragility fracture risk factors [1].

For patients on continuous, adequate-dose testosterone, routine DEXA scanning is not required before age 50 in the absence of additional risk factors. After oophorectomy, annual verification that testosterone levels remain in the male reference range becomes especially important, as there is no longer a gonadal estrogen safety net.

Screening for Reproductive Organs

Transmasculine patients who retain a cervix, uterus, or ovaries require organ-specific cancer screening per general population guidelines. Testosterone therapy does not eliminate the need for cervical cancer screening. The American Cancer Society guidelines recommend cervical screening starting at age 25 with primary HPV testing every 5 years, or co-testing (HPV plus cytology) every 5 years, or cytology alone every 3 years [10].

Vaginal atrophy from testosterone may make speculum exams uncomfortable. Use a pediatric speculum, offer self-swab HPV collection where available, and consider topical vaginal estrogen (which does not meaningfully affect serum estradiol levels) to reduce discomfort.

Endometrial monitoring via transvaginal ultrasound is not routinely required unless the patient experiences unexpected vaginal bleeding after menses have ceased on testosterone. A 2019 prospective study in the Journal of Clinical Endocrinology and Metabolism found that endometrial thickness remained <4 mm in 94% of transmasculine patients after 12 months of testosterone therapy, with no cases of endometrial hyperplasia detected at biopsy [11].

Mental Health and Quality-of-Life Monitoring

Lab values alone do not capture the full picture. Structured mental health check-ins should occur at every clinical visit during the first year and at least annually thereafter.

A 2022 systematic review and meta-analysis in Psychoneuroendocrinology synthesizing data from 19 studies (N=3,707) found that testosterone GAHT was associated with a 32% reduction in depression symptom scores (standardized mean difference: -0.58 to 95% CI -0.73 to -0.43) and a 27% reduction in anxiety scores at 12 months [12]. These improvements appeared within the first 3 to 6 months and remained stable through 24 months.

Monitoring should include validated screening instruments such as the PHQ-9 for depression and GAD-7 for anxiety. If scores worsen despite adequate testosterone levels, evaluate for external stressors, minority stress burden, and comorbid psychiatric conditions rather than assuming the hormonal regimen is inadequate.

Subcutaneous vs. Intramuscular: Does the Route Change the Monitoring?

Subcutaneous injection of testosterone cypionate has gained widespread acceptance in GAHT, though it too is technically off-label (the FDA label specifies intramuscular administration). A 2017 study in Transgender Health compared pharmacokinetics of subcutaneous versus intramuscular testosterone cypionate in 63 transmasculine patients and found no statistically significant difference in trough testosterone levels, hematocrit, or lipid profiles at 6 months [13].

The monitoring schedule does not change based on injection route. Draw the same labs at the same intervals. The practical advantage of subcutaneous injection is patient comfort and self-administration ease, which improves adherence. Higher adherence means more reliable trough levels, which in turn makes lab interpretation more straightforward.

Drug Interactions That Affect Monitoring

Testosterone cypionate has pharmacokinetic interactions that can affect lab values or clinical outcomes. The most clinically relevant interactions for transmasculine patients include:

Anticoagulants (warfarin, direct oral anticoagulants): testosterone can increase warfarin sensitivity. Monitor INR more frequently (every 2 weeks) when initiating testosterone in a patient already on warfarin. Corticosteroids: concurrent use increases fluid retention risk and may worsen glucose tolerance. Monitor fasting glucose or HbA1c at 3-month intervals rather than 6-month if corticosteroids are co-prescribed. Insulin and oral hypoglycemics: testosterone may improve insulin sensitivity over time, potentially requiring dose reductions in diabetic patients. The FDA prescribing information for testosterone cypionate specifically warns of hypoglycemia risk in patients on diabetes medications [14].